UM  > 中華醫藥研究院
Peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges
Wai San Cheang1; Xiao Yu Tian2; Wing Tak Wong2; Yu Huang1
2015-12
Source PublicationBRITISH JOURNAL OF PHARMACOLOGY
ISSN0007-1188
Volume172Issue:23Pages:5512-5522
Abstract

The peroxisome proliferator-activated receptors, PPAR, PPAR/ and PPAR, are ligand-activated transcriptional factors belonging to the nuclear receptors superfamily and they are known to play important roles in glucose and lipid metabolism. Experimental studies in animal models of metabolic diseases have also revealed that activation of PPARs protects against the vascular complications of diabetes, hypertension, atherosclerosis, myocardial infarction and stroke, through exerting their anti-inflammatory, anti-atherogenic and antioxidant effects. In clinical trials and post-market surveillance, agonists of PPARs have been shown to effectively prevent cardiovascular events. However, adverse effects, particularly for PPAR agonists, are also observed with the use of investigational PPAR agonists and even some approved drugs. Further exploration of underlying mechanisms is needed to develop novel ways of PPAR activation without causing serious side effects. This article reviews the cardiovascular effects of PPARs, with emphasis on the therapeutic potential of PPAR agonists in combating metabolic vascular diseases.
 

DOIhttps://doi.org/10.1111/bph.13029
Indexed BySCI
Language英语
WOS Research AreaPharmacology & Pharmacy
WOS SubjectPharmacology & Pharmacy
WOS IDWOS:000366392500009
Fulltext Access
Citation statistics
Cited Times [WOS]:25   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
Corresponding AuthorYu Huang
Affiliation1.Shenzhen Research Institute, Institute of Vascular Medicine and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China
2.Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, USA
Recommended Citation
GB/T 7714
Wai San Cheang,Xiao Yu Tian,Wing Tak Wong,et al. Peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges[J]. BRITISH JOURNAL OF PHARMACOLOGY,2015,172(23):5512-5522.
APA Wai San Cheang,Xiao Yu Tian,Wing Tak Wong,&Yu Huang.(2015).Peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.BRITISH JOURNAL OF PHARMACOLOGY,172(23),5512-5522.
MLA Wai San Cheang,et al."Peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges".BRITISH JOURNAL OF PHARMACOLOGY 172.23(2015):5512-5522.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Wai San Cheang]'s Articles
[Xiao Yu Tian]'s Articles
[Wing Tak Wong]'s Articles
Baidu academic
Similar articles in Baidu academic
[Wai San Cheang]'s Articles
[Xiao Yu Tian]'s Articles
[Wing Tak Wong]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Wai San Cheang]'s Articles
[Xiao Yu Tian]'s Articles
[Wing Tak Wong]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.